Mediwhale's 'Dr. Noon CVD' Cardiovascular AI Surpasses 100 Medical Institutions

Mediwhale's innovative retinal AI prediction solution, 'Dr. NooN CVD,' has secured 111 paid user institutions domestically and internationally approximately two years after its launch, proving strong market trust. This solution, which has surpassed 40,000 cumulative uses, recorded explosive growth this year, particularly as its adoption accelerated, primarily in internal medicine departments, through an agreement with Dong-A ST. 'Dr. NooN CVD' is a groundbreaking medical AI software that predicts the risk of future cardiovascular disease with accuracy comparable to cardiac CT, simply through an easy eye exam. Recognized for its significantly higher accessibility and efficiency compared to existing examinations such as cardiac CT or carotid ultrasound, it is rapidly spreading beyond Korea to medical sites worldwide, including Europe and the Middle East. Mediwhale is leading a change in the medical paradigm, having solidly demonstrated on the global stage that retinal AI can accurately assess cardiovascular, renal, and metabolic functions. This is evidenced by the acceptance of over 10 research abstracts and invitations to speak at key sessions at major global cardiovascular societies such as the European Society of Cardiology (ESC) and the American Heart Association (AHA). While accelerating global market expansion with the goal of securing De Novo FDA approval for 'Dr. NooN CVD' next year, Mediwhale is also preparing for the domestic launch of 'Dr. NooN CKD,' a retinal AI-based chronic kidney disease prediction solution. Since 'Dr. NooN CKD' was designated as an innovative medical device, its pivotal clinical trials for Ministry of Food and Drug Safety approval are proceeding smoothly. Choi Tae-geun, CEO of Mediwhale, emphasized, "The rapid spread of Dr. NooN CVD is an achievement that demonstrates the market's strong trust in Mediwhale's technology." He further stated his ambition, "Using next year's FDA approval and the launch of Dr. NooN CKD as a stepping stone, we will actively expand our domestic and international markets and accelerate sales growth." Mediwhale plans to contribute to improving the health of people worldwide with its innovative retinal AI technology and emerge as a leader in the medical AI market.